trending Market Intelligence /marketintelligence/en/news-insights/trending/udeb0HJl5cfYZdsw50Xd3g2 content esgSubNav
In This List

Zogenix reverts rights to psychosis drug back to DURECT

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Zogenix reverts rights to psychosis drug back to DURECT

DURECT Corp. and Zogenix Inc. terminated a 2011 agreement to develop and commercialize a psychosis treatment.

Zogenix completed several phase 1 clinical trials for the investigational drug Relday and reported that it was generally safe and well-tolerated.

The company returned development and commercialization rights to Durect and will also transfer all regulatory filings and development information.